Venetoclax, a specific BCL-2 inhibitor, demonstrated in preclinical tests an increase in the apoptotic rate in CML cells and presented a synergistic effect with TKI against CD34-positive CML cells [272,273]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.